clinical trial · NCT06664125
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
Jemincare·phase2·recruiting·n = 50
HyperphosphatemiaJMKX003002 will be administered orallySevelamer carbonate
brief summary
A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
started
Dec 30, 2024
primary completion
Jun 30, 2025
completion
Sep 30, 2025
last updated
Feb 3, 2025
detailed description
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
official title
A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol